Analyst Price Targets — RAPT
Latest News for RAPT
FCPM III Services bought 1,489,096 RAPT shares last quarter. The quarter-end position value rose by $53.22 million, reflecting both trading and stock price movement.
OrbiMed Advisors increased its position in RAPT Therapeutics by 556,273 shares during the fourth quarter; the estimated trade size was $17.28 million based on quarterly average pricing. The quarter-end value of the RAPT stake rose by $27.62 million, reflecting both additional shares and stock price appreciation.
Great Point Partners acquired 581,187 shares of RAPT Therapeutics in the fourth quarter. The quarter-end position value increased by $19.68 million due to the new position in RAPT Therapeutics.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation.
Rapt Therapeutics (NASDAQ: RAPT - Get Free Report) and Solid Biosciences (NASDAQ: SLDB - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability. Profitability This table compares Rapt Therapeutics and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RAPT.
U.S. House Trading
No House trades found for RAPT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.